This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Asmar, R. Articles by Shepherd, G. L Search for Related Content PubMed PubMed Citation Articles by Asmar, R. Articles by Shepherd, G. L Social Bookmarking                         What's this?

Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension

The Cardiovascular Institute, Paris, France, ra{at}icv.org

Phillipe Gosse

Hôpital St André, Bordeaux, France

Jirar Topouchian

The Cardiovascular Institute, Paris, France

Gilbert N'tela

Hôpital St André, Bordeaux, France

Amanda Dudley

GlaxoSmithKline, Greenford, UK

Gillian L Shepherd

GlaxoSmithKline, Greenford, UK

Arterial wall stiffness, an important independent risk factor for cardiovascular disease in patients with hypertension, is worsened by the coexistence of diabetes mellitus. This randomised, prospective, double-blind, crossover trial assessed the effects of telmisartan on arterial stiffness in patients with Type 2 diabetes with essential hypertension. After a two-week placebo wash out period, 28 ambulatory patients received telmisartan (40 mg) or placebo for three weeks. Following a second two-week placebo wash out period, patients received the alternate treatment for a further three weeks. Augmentation index and central blood pressure (BP) were determined using the SphygmoCor^TM device and pulse wave velocity (PWV) was measured using an automatic device, the Complior^TM, at the beginning and the end of each period. Telmisartan significantly reduced the carotid—femoral PWV compared with placebo (mean adjusted treatment difference —0.95 m/s; 95% CI: —1.67, —0.23 m/s; p=0.013). Peripheral and central diastolic, systolic and pulse pressures were also significantly reduced with telmisartan compared with placebo. In conclusion, telmisartan reduces arterial stiffness and peripheral and central BPs as assessed by PWV and pulse contour analysis in hypertensive patients with Type 2 diabetes. These properties of telmisartan suggest that it may improve cardiovascular outcome in this patient population.

Key Words: telmisartan • diabetes • hypertension • pulse wave velocity • stiffness • blood pressure • angiotensin II receptor blocker • pulse pressure

Journal of Renin-Angiotensin-Aldosterone System, Vol. 3, No. 3, 176-180 (2002)
DOI: 10.3317/jraas.2002.038


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. R. Khoshdel, S. L. Carney, B. R. Nair, and A. Gillies Better Management of Cardiovascular Diseases by Pulse Wave Velocity: Combining Clinical Practice with Clinical Research using Evidence-Based Medicine Clin. Med. Res., March 1, 2007; 5(1): 45 - 52. [Abstract] [Full Text] [PDF]

				H. H. Dao, R. Essalihi, C. Bouvet, and P. Moreau Evolution and modulation of age-related medial elastocalcinosis: Impact on large artery stiffness and isolated systolic hypertension Cardiovasc Res, May 1, 2005; 66(2): 307 - 317. [Abstract] [Full Text] [PDF]